MA35104B1 - Inhibiteur du virus de l'hepatite c - Google Patents

Inhibiteur du virus de l'hepatite c

Info

Publication number
MA35104B1
MA35104B1 MA36399A MA36399A MA35104B1 MA 35104 B1 MA35104 B1 MA 35104B1 MA 36399 A MA36399 A MA 36399A MA 36399 A MA36399 A MA 36399A MA 35104 B1 MA35104 B1 MA 35104B1
Authority
MA
Morocco
Prior art keywords
hepatitis
virus
inhibitor
compounds
vhc
Prior art date
Application number
MA36399A
Other languages
English (en)
Inventor
Qi Chen
Omar D Lopez
John A Bender
Gan Wang
Van N Nguyen
John F Kadow
Nicholas A Meanwell
Makonen Belema
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46147738&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA35104(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MA35104B1 publication Critical patent/MA35104B1/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41781,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention concerne des composés, des compositions et méthodes pour le traitement d'une infection par le virus de l'hépatite c (vhc) de la formule (i) suivante. L'invention concerne également des compositions pharmaceutiques contenant de tels composés et des procédés d'utilisation de ces composés dans le traitement d'une infection par le vhc.
MA36399A 2011-05-12 2013-11-07 Inhibiteur du virus de l'hepatite c MA35104B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161485224P 2011-05-12 2011-05-12
US13/465,298 US9546160B2 (en) 2011-05-12 2012-05-07 Hepatitis C virus inhibitors
PCT/US2012/037012 WO2012154777A1 (fr) 2011-05-12 2012-05-09 Inhibiteurs du virus de l'hépatite c

Publications (1)

Publication Number Publication Date
MA35104B1 true MA35104B1 (fr) 2014-05-02

Family

ID=46147738

Family Applications (1)

Application Number Title Priority Date Filing Date
MA36399A MA35104B1 (fr) 2011-05-12 2013-11-07 Inhibiteur du virus de l'hepatite c

Country Status (21)

Country Link
US (1) US9546160B2 (fr)
EP (1) EP2707365B1 (fr)
JP (1) JP5977819B2 (fr)
KR (1) KR20140037114A (fr)
CN (1) CN103827108B (fr)
AR (1) AR086389A1 (fr)
AU (1) AU2012253578A1 (fr)
BR (1) BR112013028679A2 (fr)
CA (1) CA2835688A1 (fr)
CL (1) CL2013003229A1 (fr)
CO (1) CO6821952A2 (fr)
EA (1) EA024201B1 (fr)
IL (1) IL229331A0 (fr)
MA (1) MA35104B1 (fr)
MX (1) MX2013012870A (fr)
PE (1) PE20150105A1 (fr)
SG (1) SG194846A1 (fr)
TW (1) TW201249834A (fr)
UY (1) UY34066A (fr)
WO (1) WO2012154777A1 (fr)
ZA (1) ZA201309356B (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8303944B2 (en) * 2006-08-11 2012-11-06 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8552047B2 (en) 2011-02-07 2013-10-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9326973B2 (en) 2012-01-13 2016-05-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2014065791A1 (fr) * 2012-10-24 2014-05-01 Bristol-Myers Squibb Company Inhibiteurs du virus de l'hépatite c
US20150023913A1 (en) 2013-07-02 2015-01-22 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US9717712B2 (en) 2013-07-02 2017-08-01 Bristol-Myers Squibb Company Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus
US9775831B2 (en) 2013-07-17 2017-10-03 Bristol-Myers Squibb Company Combinations comprising biphenyl derivatives for use in the treatment of HCV
EP3080104A1 (fr) * 2013-12-11 2016-10-19 Bristol-Myers Squibb Company Dérivés de 4,4'-biphényldiyl bis-(1h-imidazolyle) comme inhibiteurs du vhc
CN104725365B (zh) * 2013-12-23 2019-02-26 南京圣和药业股份有限公司 丙型肝炎病毒抑制剂及其应用
CN104860931A (zh) * 2014-02-21 2015-08-26 常州寅盛药业有限公司 丙肝病毒抑制剂及其制药用途
WO2017023631A1 (fr) 2015-08-06 2017-02-09 Bristol-Myers Squibb Company Inhibiteurs du virus de l'hépatite c
CN115073308A (zh) * 2021-03-15 2022-09-20 苏州信礼发医药技术有限公司 1-氨甲基-1-环丙醇的合成方法
WO2023283425A1 (fr) 2021-07-09 2023-01-12 Plexium, Inc. Composés aryle et compositions pharmaceutiques modulant l'ikzf2

Family Cites Families (140)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0679153A4 (fr) 1993-01-14 1996-05-15 Magainin Pharma Acides amines et peptides a terminaisons modifiees.
US5654451B1 (en) 1993-01-14 2000-02-22 Magainin Pharma Amino acids and peptides having modified c-terminals and modified n-terminals
WO2004005264A2 (fr) 2002-07-05 2004-01-15 Axxima Pharmaceuticals Ag Composes d'imidazole et proteines cellulaires humaines caseine kinase i alpha, delta et epsilon utilises comme cible lors d'interventions medicales contre des infections par le virus de l'hepatite c
AU2003264038A1 (en) 2002-08-12 2004-02-25 Bristol-Myers Squibb Company Combination pharmaceutical agents as inhibitors of hcv replication
WO2006022442A1 (fr) 2004-08-24 2006-03-02 Santen Pharmaceutical Co., Ltd. Nouveaux derives d’amides heterocycliques ayant une activite d’inhibition de la dihydroorotate deshydrogenase
GB2438802A (en) 2005-02-28 2007-12-05 Univ Rockefeller Structure of the hepatitis C virus NS5A protein
US8143288B2 (en) 2005-06-06 2012-03-27 Bristol-Myers Squibb Company Inhibitors of HCV replication
EP1940786B1 (fr) 2005-09-16 2010-08-18 Arrow Therapeutics Limited Dérivés de biphényle et leur utilisation dans le traitement de l'hépatite c
WO2007058384A1 (fr) 2005-11-17 2007-05-24 Osaka University Procede d'inhibition de la replication du virus de l'hepatite c, inhibiteur de replication du virus et procede de selection de cet inhibiteur
WO2007081517A2 (fr) 2005-12-21 2007-07-19 Abbott Laboratories Composes anti-viraux
WO2007076034A2 (fr) 2005-12-21 2007-07-05 Abbott Laboratories Composes antiviraux
SG133452A1 (en) 2005-12-30 2007-07-30 Novartis Ag Peptide deformylase inhibitors for treatment of mycobacterial and other parasitic diseases
BRPI0712806A2 (pt) 2006-05-30 2012-10-23 Arrow Therapeutics Ltd uso de um composto, derivado de bifenila ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, produto, e, método para melhorar uma infecção por hepatite c em um paciente
US20100158862A1 (en) 2006-08-11 2010-06-24 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US7659270B2 (en) 2006-08-11 2010-02-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8329159B2 (en) 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7745636B2 (en) 2006-08-11 2010-06-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8303944B2 (en) 2006-08-11 2012-11-06 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN101558059B (zh) * 2006-08-11 2014-12-03 百时美施贵宝公司 丙型肝炎病毒抑制剂
US7759495B2 (en) 2006-08-11 2010-07-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2008070447A2 (fr) 2006-11-21 2008-06-12 Smithkline Beecham Corporation Composés anti-viraux
TWI399380B (zh) 2006-12-20 2013-06-21 Abbott Lab 抗病毒化合物
US7741347B2 (en) 2007-05-17 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8629171B2 (en) 2007-08-08 2014-01-14 Bristol-Myers Squibb Company Crystalline form of methyl ((1S)-1-((25)-2-(5-(4'-(2-((25)-1((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate dihydrochloride salt
US7728027B2 (en) 2007-08-08 2010-06-01 Bristol-Myers Squibb Company Process for synthesizing compounds useful for treating hepatitis C
CN102015692A (zh) 2008-02-12 2011-04-13 百时美施贵宝公司 丙型肝炎病毒抑制剂
US8147818B2 (en) * 2008-02-13 2012-04-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7704992B2 (en) 2008-02-13 2010-04-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7906655B2 (en) 2008-08-07 2011-03-15 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8383094B2 (en) 2008-10-01 2013-02-26 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8729077B2 (en) 2008-11-28 2014-05-20 Glaxosmithkline Llc Anti-viral compounds, compositions, and methods of use
CN104163816A (zh) 2008-12-03 2014-11-26 普雷西迪奥制药公司 Hcv ns5a的抑制剂
CA2750577A1 (fr) 2008-12-03 2010-06-10 Presidio Pharmaceuticals, Inc. Inhibiteurs du virus de l'hepatite c de type ns5a
US8541424B2 (en) 2008-12-23 2013-09-24 Abbott Laboratories Anti-viral compounds
WO2010091413A1 (fr) 2009-02-09 2010-08-12 Enanta Pharmaceuticals, Inc. Dérivés du dibenzimidazole liés
WO2010096462A1 (fr) 2009-02-17 2010-08-26 Enanta Pharmaceuticals, Inc Dérivés du diimidazole lié
TWI438200B (zh) 2009-02-17 2014-05-21 必治妥美雅史谷比公司 C型肝炎病毒抑制劑
CA2753313A1 (fr) 2009-02-23 2010-08-26 Presidio Pharmaceuticals, Inc. Inhibiteurs du ns5a du vhc
WO2010094977A1 (fr) 2009-02-23 2010-08-26 Arrow Therapeutics Limited Nouveaux composés de biphényle utiles pour le traitement de l'hépatite c
MY160130A (en) 2009-02-27 2017-02-28 Enanta Pharm Inc Hepatitis c virus inhibitors
ME02418B (fr) 2009-03-27 2016-09-20 Merck Sharp & Dohme Inhibiteurs de la réplication du virus de l'hépatite c
EP2410843A4 (fr) 2009-03-27 2012-08-08 Presidio Pharmaceuticals Inc Inhibiteurs à noyaux fusionnés de l'hépatite c
CA2756255A1 (fr) 2009-03-27 2010-09-30 Presidio Pharmaceuticals, Inc. Inhibiteurs bicycliques du vhc substitues
US20110237636A1 (en) 2009-03-30 2011-09-29 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US8796466B2 (en) 2009-03-30 2014-08-05 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
TWI476190B (zh) 2009-03-30 2015-03-11 必治妥美雅史谷比公司 C型肝炎病毒抑制劑
TW201038559A (en) 2009-04-09 2010-11-01 Bristol Myers Squibb Co Hepatitis C virus inhibitors
US8143414B2 (en) 2009-04-13 2012-03-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
RU2541571C2 (ru) 2009-04-15 2015-02-20 Эббви Инк. Противовирусные соединения
BRPI1016172A2 (pt) 2009-04-24 2016-04-19 Tibotec Pharm Ltd éteres diarílicos
CA2760205A1 (fr) 2009-05-12 2010-11-18 Schering Corporation Composes aryles tricycliques condenses utiles pour le traitement de maladies virales
AP3622A (en) 2009-05-13 2016-03-02 Gilead Sciences Inc Antiviral compounds
CA2762885A1 (fr) 2009-05-29 2010-12-02 Schering Corporation Composes antiviraux constitues de trois fractions d'aryle alignees pour traiter des maladies telles que l'hepatite c
US8138215B2 (en) 2009-05-29 2012-03-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8211928B2 (en) 2009-05-29 2012-07-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2435424B1 (fr) 2009-05-29 2015-01-21 Merck Sharp & Dohme Corp. Composés antiviraux de trois fractions d'aryle liées pour traiter des maladies telles que l'hépatite c
US9394279B2 (en) 2009-06-11 2016-07-19 Abbvie Inc. Anti-viral compounds
SG171708A1 (en) 2009-06-11 2011-07-28 Abbott Lab Anti-viral compounds to treat hcv infection
US8937150B2 (en) 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
WO2010148006A1 (fr) 2009-06-16 2010-12-23 Enanta Pharmaceuticals, Inc. Inhibiteurs du virus de l'hépatite c
WO2011004276A1 (fr) 2009-07-06 2011-01-13 Pfizer Limited Inhibiteurs du virus de l’hépatite c
JP2012533569A (ja) 2009-07-16 2012-12-27 ヴァーテックス ファーマシューティカルズ、 インコーポレイテッド フラビウイルス感染症を治療又は予防するためのベンゾイミダゾール類似体
RU2538507C2 (ru) 2009-08-07 2015-01-10 Тиботек Фармасьютикалз Фенилэтинильные производные в качестве ингибиторов вируса гепатита с
CN102471324B (zh) 2009-08-07 2014-12-17 泰博特克药品公司 作为丙型肝炎病毒抑制剂的双苯并咪唑衍生物
AU2010291215A1 (en) 2009-09-03 2012-02-23 Janssen Sciences Ireland Uc Bis-benzimidazole derivatives
EP2473056A4 (fr) 2009-09-04 2013-02-13 Glaxosmithkline Llc Composés chimiques
EP2475256A4 (fr) 2009-09-11 2013-06-05 Enanta Pharm Inc Inhibiteurs du virus de l'hépatite c
EP2475254A4 (fr) 2009-09-11 2013-05-22 Enanta Pharm Inc Inhibiteurs du virus de l'hépatite c
US8415374B2 (en) 2009-10-12 2013-04-09 Bristol-Myers Squibb Company Combinations of hepatitis C virus inhibitors
WO2011050146A1 (fr) 2009-10-23 2011-04-28 Glaxosmithkline Llc Composés chimiques
UA108211C2 (uk) 2009-11-04 2015-04-10 Янссен Рід Айрленд Бензімідазолімідазольні похідні
US20110274648A1 (en) 2009-11-11 2011-11-10 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20110269956A1 (en) 2009-11-11 2011-11-03 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20110281910A1 (en) 2009-11-12 2011-11-17 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20120276047A1 (en) 2009-11-25 2012-11-01 Rosenblum Stuart B Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases
MY179840A (en) 2009-12-04 2020-11-18 National Health Res Inst Proline derivatives
EP2512480A4 (fr) 2009-12-14 2013-05-15 Enanta Pharm Inc Inhibiteurs du virus de l'hépatite c
US8377980B2 (en) 2009-12-16 2013-02-19 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN102791687B (zh) 2009-12-18 2015-02-11 北京凯因科技股份有限公司 C型肝炎病毒复制的新型抑制剂
RU2554087C2 (ru) 2009-12-18 2015-06-27 Айденикс Фармасьютикалз, Инк. 5,5-конденсированные ариленовые или гетероариленовые ингибиторы вируса гепатита с
CA2785488A1 (fr) 2009-12-22 2011-07-21 Merck Sharp & Dohme Corp. Composes tricycliques fusionnes et leurs methodes d'utilisation pour le traitement de maladies virales
JP2013515746A (ja) 2009-12-24 2013-05-09 ヴァーテックス ファーマシューティカルズ、 インコーポレイテッド フラビウイルス感染症の治療又は予防のための類似体
US8362020B2 (en) 2009-12-30 2013-01-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2011091446A1 (fr) 2010-01-22 2011-07-28 Glaxosmithkline Llc Composés chimiques
CA2787309A1 (fr) 2010-01-25 2011-07-28 Enanta Pharmaceuticals, Inc. Inhibiteurs du virus de l'hepatite c
JP2013518062A (ja) 2010-01-28 2013-05-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング C型肝炎阻害化合物
US8178531B2 (en) 2010-02-23 2012-05-15 Enanta Pharmaceuticals, Inc. Antiviral agents
US8623814B2 (en) 2010-02-23 2014-01-07 Enanta Pharmaceuticals, Inc. Antiviral agents
KR20120124495A (ko) 2010-03-04 2012-11-13 이난타 파마슈티칼스, 인코포레이티드 Hcv 복제의 억제제로서의 조합 제약 작용제
BR112012022125A2 (pt) * 2010-03-09 2016-11-01 Merck Sharp & Dhme Corp composto, sal de dicloridrato, composição farmacêutica, uso do composto, e, método para tratar um paciente
TW201141857A (en) 2010-03-24 2011-12-01 Vertex Pharma Analogues for the treatment or prevention of flavivirus infections
EP2550278A1 (fr) 2010-03-24 2013-01-30 Vertex Pharmaceuticals Incorporated Analogues pour traiter ou prévenir les infections à flavivirus
MX2012010918A (es) 2010-03-24 2013-01-18 Vertex Pharma Analogos para el tratamiento o prevencion de infecciones por flavivirus.
WO2011127350A1 (fr) 2010-04-09 2011-10-13 Enanta Pharmaceuticals, Inc. Inhibiteurs du virus de l'hépatite c
US20110312996A1 (en) 2010-05-17 2011-12-22 Intermune, Inc. Novel inhibitors of hepatitis c virus replication
WO2011149856A1 (fr) 2010-05-24 2011-12-01 Presidio Pharmaceuticals, Inc. Inhibiteurs de ns5a du vhc
WO2011150243A1 (fr) 2010-05-28 2011-12-01 Presidio Pharmaceuticals, Inc. Inhibiteurs de ns5a de vhc
WO2011153396A1 (fr) 2010-06-04 2011-12-08 Enanta Pharmaceuticals, Inc Inhibiteurs du virus de l'hépatite c
WO2011156543A2 (fr) 2010-06-09 2011-12-15 Presidio Pharmaceuticals, Inc. Inhibiteurs de la protéine ns5a du vhc
NZ605440A (en) 2010-06-10 2014-05-30 Abbvie Bahamas Ltd Solid compositions comprising an hcv inhibitor
WO2011154871A1 (fr) 2010-06-10 2011-12-15 Pfizer Limited Inhibiteurs du virus de l'hépatite c
WO2012003642A1 (fr) 2010-07-09 2012-01-12 Merck Sharp & Dohme Corp. Composés tricycliques condensés et leur utilisation pour le traitement de maladies virales
AU2011286276A1 (en) 2010-07-26 2013-01-24 Merck Sharp & Dohme Corp. Substituted biphenylene compounds and methods of use thereof for the treatment of viral diseases
WO2012013643A1 (fr) 2010-07-26 2012-02-02 Tibotec Pharmaceuticals Dérivés hétéro-bicycliques en tant qu'inhibiteurs du vhc
BR112013002729A2 (pt) 2010-08-04 2016-05-31 Bristol Myers Squibb Co inibidores de vírus de hepatite c
US20120196794A1 (en) 2010-08-06 2012-08-02 Bristol-Myers Squibb Company Combinations of Hepatitis C Virus Inhibitors
WO2012021704A1 (fr) 2010-08-12 2012-02-16 Enanta Pharmaceuticals, Inc. Inhibiteurs du virus de l'hépatite c
US20120195857A1 (en) 2010-08-12 2012-08-02 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
WO2012020036A1 (fr) 2010-08-13 2012-02-16 F. Hoffmann-La Roche Ag Inhibiteurs du virus de l'hépatite c
US8859595B2 (en) 2010-08-26 2014-10-14 Rfs Pharma, Llc Potent and selective inhibitors of hepatitis C virus
US8822520B2 (en) 2010-09-22 2014-09-02 Presidio Pharmaceuticals, Inc. Substituted bicyclic HCV inhibitors
WO2012040923A1 (fr) 2010-09-29 2012-04-05 Merck Sharp & Dohme Corp. Dérivés d'indoles tétracycliques et leurs méthodes d'utilisation pour le traitement de maladies virales
US8999967B2 (en) 2010-09-29 2015-04-07 Presidio Pharmaceuticals, Inc. Tricyclic fused ring inhibitors of hepatitis C
WO2012040924A1 (fr) 2010-09-29 2012-04-05 Merck Sharp & Dohme Corp. Composés hétérocycliques tétracycliques condensés et leurs méthodes d'utilisation pour le traitement de maladies virales
EP2621932A4 (fr) 2010-09-29 2014-03-26 Merck Sharp & Dohme Composés hétérocycliques tétracycliques pour le traitement d'une infection par le virus de l'hépatite c
CA2811662A1 (fr) 2010-09-29 2012-04-05 Merck Sharp & Dohme Corp. Derives d'indoles tetracycliques pour le traitement d'une infection par le virus de l'hepatite c
WO2012050848A1 (fr) 2010-09-29 2012-04-19 Schering Corporation Dérivés tétracycliques condensés et procédés d'utilisation de ceux-ci dans le traitement de maladies virales
RU2013119607A (ru) 2010-09-29 2014-11-10 Мерк Шарп Энд Домэ Корп. Полициклические гетероциклические соединения и способы их применения для лечения вирусных заболеваний
WO2012048421A1 (fr) 2010-10-14 2012-04-19 Boehringer Ingelheim International Gmbh Composés inhibiteurs de l'hépatite c
CN103189371B (zh) 2010-11-04 2015-04-01 施万生物制药研发Ip有限责任公司 丙型肝炎病毒抑制剂
KR20190140486A (ko) 2010-11-17 2019-12-19 길리애드 파마셋 엘엘씨 항바이러스 화합물
RU2452735C1 (ru) 2010-11-30 2012-06-10 Александр Васильевич Иващенко Замещенные азолы, противовирусный активный компонент, фармацевтическая композиция, способ получения и применения
US20150031884A1 (en) 2010-12-15 2015-01-29 Abbvie Inc. Anti-viral compounds
WO2012083059A1 (fr) 2010-12-15 2012-06-21 Abbott Laboratories Composés anti-viraux
WO2012083058A2 (fr) 2010-12-15 2012-06-21 Abbott Laboratories Composés anti-viraux
WO2012083048A2 (fr) 2010-12-15 2012-06-21 Abbott Laboratories Composés anti-viraux
EP2651923A4 (fr) 2010-12-15 2014-06-18 Abbvie Inc Composés anti-viraux
US20140364617A1 (en) 2010-12-15 2014-12-11 Abbvie Inc. Anti-viral compounds
EP2651885A1 (fr) 2010-12-16 2013-10-23 Abbvie Inc. Composés antiviraux
MX2013006828A (es) 2010-12-16 2014-10-14 Abbvie Inc Compuestos antivirales.
WO2012087976A2 (fr) 2010-12-21 2012-06-28 Intermune, Inc. Nouveaux inhibiteurs de la réplication du virus de l'hépatite c
US8552047B2 (en) 2011-02-07 2013-10-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2012123298A1 (fr) 2011-03-11 2012-09-20 F. Hoffmann-La Roche Ag Composés antiviraux
WO2012122716A1 (fr) 2011-03-17 2012-09-20 Merck Sharp & Dohme Corp. Dérivés tétracycliques de xanthène et leurs procédés d'utilisation pour le traitement de maladies virales
US20120252721A1 (en) 2011-03-31 2012-10-04 Idenix Pharmaceuticals, Inc. Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
WO2012162580A2 (fr) 2011-05-26 2012-11-29 Abbvie Inc Composés antiviraux
WO2012162578A2 (fr) 2011-05-26 2012-11-29 Abbvie Inc. Composés antiviraux
AP2013007263A0 (en) 2011-05-27 2013-11-30 Achillion Pharmaceuticals Inc Substituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenesuseful for treating HCV infections
WO2012175581A1 (fr) 2011-06-24 2012-12-27 F. Hoffmann-La Roche Ag Composés antiviraux
US9303061B2 (en) 2011-07-09 2016-04-05 Sunshine Luke Pharma Co., Ltd. Spiro compounds as Hepatitis C virus inhibitors

Also Published As

Publication number Publication date
CL2013003229A1 (es) 2014-09-05
US20130121957A1 (en) 2013-05-16
EA024201B1 (ru) 2016-08-31
BR112013028679A2 (pt) 2017-01-24
EP2707365A1 (fr) 2014-03-19
CA2835688A1 (fr) 2012-11-15
WO2012154777A1 (fr) 2012-11-15
AR086389A1 (es) 2013-12-11
KR20140037114A (ko) 2014-03-26
SG194846A1 (en) 2013-12-30
EA201391685A1 (ru) 2014-03-31
CN103827108A (zh) 2014-05-28
JP5977819B2 (ja) 2016-08-24
EP2707365B1 (fr) 2018-10-17
CO6821952A2 (es) 2013-12-31
ZA201309356B (en) 2015-05-27
AU2012253578A1 (en) 2014-01-16
CN103827108B (zh) 2018-05-15
MX2013012870A (es) 2014-02-20
US9546160B2 (en) 2017-01-17
UY34066A (es) 2012-11-30
JP2014513690A (ja) 2014-06-05
PE20150105A1 (es) 2015-02-06
TW201249834A (en) 2012-12-16
IL229331A0 (en) 2014-01-30

Similar Documents

Publication Publication Date Title
MA35104B1 (fr) Inhibiteur du virus de l'hepatite c
MA34896B1 (fr) Inhibiteurs du virus de l'hepatite c
MA33731B1 (fr) Inhibiteurs du virus de l'hépatite c
MA35750B1 (fr) Dérivés de nucléoside substitué 2',4'-difluoro-2'-méthyle en tant qu'inhibiteurs de la réplication de l'arn du vhc (virus de l'hépatite c)
MA35132B1 (fr) 4-aryl-n-phényl-1,3,5-triazine-2- amines contenant un groupe sulfoximine
MA37712B1 (fr) Inhibiteurs macrocycliques de virus flaviviridae
MA37942B1 (fr) Hétéroaryldihydropyrimidines d'acide 6-aminé pour le traitement et la prophylaxie d'une infection par le virus de l'hépatite b
MA37891A1 (fr) Alcoxypyrazoles comme activateurs de guanylate cyclase soluble
MA35109B1 (fr) Derives de nucleoside 2-substitues et procedes d'utilisation de ceux-ci pour le traitement de maladies virales
MA29240B1 (fr) Derives d'indole pour le traitement d'infections virales
MA35749B1 (fr) Dérivés nucléosidiques 4'-azido, 3'-fluoro substitués en tant qu'inhibiteurs de la réplication de l'arn du vhc
MA32468B1 (fr) Derives de thiophene ou de thiazole et leur utilisation comme inhibiteurs de pi3k
EA201201031A1 (ru) Ингибиторы вируса гепатита с
MA34147B1 (fr) Composes tricycliques fusionnes de silyle et leurs methodes d'utilisation dans le cadre du traitement de maladies virales
MA37400B1 (fr) Composés hétérocyclyle en tant qu'inhibiteurs de mek
MX2010005292A (es) Inhibidores de la replicacion del virus de la inmunodeficiencia humana.
MA32471B1 (fr) Composés de borates esters et compositions pharmaceutiques contenant des composés
MX2010009995A (es) Heterociclos puenteados como inhibidores de la integrasa del virus de inmunodeficiencia humana.
MA34400B1 (fr) Dérivés d'acide 2-quinolinyl-acétique en tant que composés antiviraux contre le vih
MA35342B1 (fr) Composés de-pipéridinyle utiles comme inhibiteurs de la tankyrase
TN2014000195A1 (fr) 2-thiopyrimidinones
MA35443B1 (fr) Composes benzofuranes pour le traitement d'infections par le virus de l'hepatite c
MA39165A1 (fr) Dérivés de benzimidazole-proline pour leurs utilisations dans le traitement du syndrome des etats crepusculaires
MA38315B1 (fr) Composés tétracycliques substitués par un hétérocycle et procédés pour les utiliser pour le traitement de maladies virales
MA37992B1 (fr) Composes inhibiteurs de protéase ns3 pour une utilisation dans le traitement de l’infection par le virus de l'hépatite c.